Locally Advanced Colon Cancer Clinical Trial
Official title:
Analysis of the Effectiveness of Neoadjuvant Chemotherapy in the Treatment of Colon Cancer Locally Advanced
Effectiveness analysis of neoadjuvant chemotherapy in the treatment of locally advanced colon cancer. ELECLA trial
Participants in this study selected patients according to homogeneous inclusion criteria and
will be treated either with a uniform protocol of neoadjuvant chemotherapy, surgery and
complementary chemotherapy (intervention group), or with the standard scheme of postoperative
surgery and chemotherapy (control group ). All patients will be studied basally through
clinical examinations and radiological and endoscopic tests usually used to reach the
diagnosis of Locally Advanced Colon Cancer . In the group of patients receiving neoadjuvant
treatment, the CT scan will be repeated after the completion of preoperative chemotherapy to
restage the disease and quantify the degree of tumor response.
Finally, the project tries to determine whether the neoadjuvant treatment scheme increases
disease-free survival (SLE) at 2 and 5 years and overall survival (OS) at 5 years. Likewise,
the toxicity derived from chemotherapy treatment and perioperative morbidity and mortality
will be analyzed to evaluate the feasibility and safety of the therapeutic procedure. The
rate of completion of chemotherapy in both groups will also be compared.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03125980 -
Perioperative Versus Postoperative CapOX Chemotherapy for Locally Advanced Colon Cancer
|
Phase 3 | |
Recruiting |
NCT04389151 -
Triplezumab Combined With CAPEOX Regimen in Neoadjuvant Therapy for Locally Advanced Colon Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05732493 -
Short-course Radiotherapy Combined With Chemotherapy and Pd-1 Inhibitor for Locally Advanced Colon Cancer(TORCH-C)
|
Phase 2 |